3 ASX blue-chip stocks to watch after this week's market volatility

Following are the top three ASX blue chip stocks to watch out for, supported by a new business contract, solid business fundamentals and a growth-led outlook.

Megaport Limited (ASX: MP1) is one of the fastest-growing AI infrastructure companies listed on ASX and is currently trading with a market capitalisation of $4.25 billion.

MP1 had announced on 29 September 2026 that its wholly owned subsidiary, Latitude.sh, has secured three further infrastructure contracts. It has a combined total contract value (TCV) of approximately $978.6 million and is expected to contribute $232.4 million in annual recurring revenue (ARR). The new contracts increase pro forma Group ARR to $1.1 billion, with more than 85% of ARR coming from North America.    

One of the new customers has made a prepayment of approximately $281.5 million prior to the delivery of the service, which the customer has committed to in order to get rapid access to the GPUs already ordered for the GPU pool.

MP1 is required for a capital expenditure of $500.3 million for the contract, primarily for high-performance NVIDIA GPUs, compute, network, and storage hardware.

Megaport has a total liquidity source of $2.19 billion and a pro forma liquidity of $362 million.

It is expected to generate a group revenue of $720-$810 million in FY27, including the compute revenue of $395-$475 million and network revenue of $325-$335 million. MP1 is expected to have a group EBITDA margin of 42-44% in FY27 and is expected to incur a group capex of $1.78-1.88 billion. 

Pro Medicus Limited (ASX: PME) is one of the top healthcare-based ASX stocks, which is currently trading at a market capitalisation of $20.58 billion.

PME had announced on 21 October 2026 that its wholly owned US subsidiary, Visage Imaging, Inc., has signed a 7-year contract for $43 million with Virtua Health. The contract is for  a unified enterprise imaging platform comprising Visage 7 Viewer, Visage 7 Workflow, Visage 7 Open Archive, and Visage 7 Cardiology.

Pro Medicus also announced on 19 October 2026 that Visage Imaging, Inc., has signed a 7-year contract for $24 million with Billings Clinic Logan Health, based in Montana, serving communities in Montana, Northern Wyoming and the western Dakotas.

CSL Limited (ASX: CSL) is one of the leading healthcare-based ASX stocks, which is currently trading at a market capitalisation of 94.77 billion and a current annual unfranked dividend yield of 2.05%.

CSL had held its Annual General Meeting 2026 on 27 October 2026. It reported a revenue of US$15.8 billion. Underlying NPATA stood at US$3.1 billion, and underlying NPAT stands at US$2.8 billion. CSL has reported a net loss of US$2.6 billion. Net cash flow from operations reached US$3.5 billion.

It has realised US$176 million of cost savings and has done partial reinvestment in commercial and pipeline. It has maintained a solid balance sheet, with the net debt/EBITDA ratio remaining flat at 1.8x, which is within the target range of 1.5x-2.0x.

CSL Limited had announced on 22 October 2026 that it was notified that a group proceeding had been filed in the Supreme Court of Victoria, which names CSL as the defendant. The proceeding is done on behalf of persons who acquired an interest in certain CSL securities between 11 February 2025 and 11 May 2026. The proceeding includes an allegation that CSL has provided misleading or inadequate disclosures about its medium-term performance and FY26 revenue and profit expectations.

(Source: Company Announcements)